Tracy Murphy
Princess Margaret Cancer Centre · 49 works · 1,731 citations · h-index 14
Top works
- Sensitive tumour detection and classification using plasma cell-free DNA methylomes
- Biological and clinical consequences of NPM1 mutations in AML
- Cytarabine and daunorubicin for the treatment of acute myeloid leukemia
- Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase‐based therapy
- Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia
- Clofarabine in the treatment of poor risk acute myeloid leukaemia
- Emerging therapies for acute myeloid leukemia: translating biology into the clinic
- Strategies to support health care providers during the COVID-19 pandemic
- Azacitidine and venetoclax for the treatment of accelerated and blast phase myeloproliferative neoplasms and chronic myelomonocytic leukemia: a case series
- Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen
- The role of DNA-demethylating agents in cancer therapy
- Cryptic genomic lesions in adverse-risk acute myeloid leukemia identified by integrated whole genome and transcriptome sequencing
- Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML
- A clinical laboratory–developed LSC17 stemness score assay for rapid risk assessment of patients with acute myeloid leukemia
- Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia
- Integration of intra-sample contextual error modeling for improved detection of somatic mutations from deep sequencing
- Enasidenib in Combination with Venetoclax in IDH2-Mutated Myeloid Malignancies: Preliminary Results of the Phase Ib/II Enaven-AML Trial
- Final Results of the Phase Ib/II Study Evaluating Enasidenib in Combination with Venetoclax in Patients with IDH2-Mutated Relapsed/Refractory Myeloid Malignancies
- Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms
- CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study